When Compression Pressure Fractures the Capsule Wall

In direct compression of microencapsulated veterinary API for oral tablets, the process bottleneck is not drug-excipient incompatibility but mechanical rupture of the polymeric shell during the compaction phase of a rotary tablet press. Formulation trials on an instrumented rotary press with precompression stations should begin with a 1,000 mg target tablet weight, a 10 mm flat-faced bevel-edged tooling set, and a main compression force window of 6–10 kN. At these loads, tablets can reach hardness values of 60–90 N without shell failure if the coating polymer level is 15–25% w/w of the microcapsule core mass and the coating is plasticized with triethyl citrate at 10–20% w/w of the polymer. The compression formulation is typically built from spray-dried lactose monohydrate with D50 90–120 µm, microcrystalline cellulose PH102 at 30–45 wt% of the fill mass, crospovidone at 2–5 wt%, and magnesium stearate at 0.5–1.0 wt%. The microencapsulated API is added at 20–40 wt% of the tablet fill mass for non-chewable products, and at 5–15 wt% when the dose is below 20 mg per tablet. Dry blending in a bin blender at 10–15 rpm for 20–30 min is sufficient for content uniformity if the blend is previously screened through a 1.0 mm mesh. The finished tablet is released under USP <701> disintegration at 37±2°C in water, with a limit of 15 min for immediate-release oral dosage forms unless a delayed-release design is expressly indicated. Dissolution is controlled by USP <711> apparatus 2 at 50 rpm, and stability is governed by USP <905> uniformity of dosage units and 21 CFR 211.166. A formulation risk arises when water wicking into the tablet matrix causes local swelling of the microcapsule shell before disintegration, which can be suppressed by pre-drying the microcapsules at 40°C to a moisture content below 2% w/w when ambient relative humidity exceeds 60%. The terminal products are oral tablets for companion animals, typically administered in feed or by pill gun; however, direct compression above 14 kN has been shown in published pharmaceutical compaction literature to increase brittle fracture of ethylcellulose wall materials when shell thickness falls below 5 µm, so the process is not suitable for ultra-thin-shelled taste-masking grades without reformulation with ductile polyacrylate coatings.

What Particle-Size Limits Govern Microencapsulated API in Veterinary Injectable Suspensions?

Injectable suspension development reverses the usual oral-dosage logic: the microcapsule is retained as a particulate rather than dissolved, so the formulation is governed by syringability, sedimentation volume, and pharmacopoeial particulate release tests. Intramuscular and subcutaneous veterinary products are commonly filled as suspensions with microencapsulated API at 10–20% w/v, using Water for Injection containing polysorbate 80 at 0.1–0.2% w/v, sodium carboxymethylcellulose at 0.3–0.6% w/v, and benzyl alcohol at 2% w/v in multi-dose containers. Terminal sterilization at 121°C for 15 min may collapse heat-softened ethylcellulose capsules, so a two-step aseptic process is preferred: the vehicle is sterilized by autoclaving, and the microencapsulated API is sterilized by gamma irradiation at 25 kGy before aseptic addition. Final dispersion is completed in a jacketed vessel under high shear at 3,000 rpm for 5 min, then passed through a 250 µm in-line filter. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, and USP <788> particulate matter for sub-visible particles. For small-volume injectables the harmonized limits are ≤6,000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm, and the microcapsule size distribution is normally set so the D99 does not exceed the 25 µm threshold when the product is intended for intravenous administration. For intramuscular or subcutaneous suspensions, larger particles may be acceptable if the product is shown to pass syringeability and local tolerance studies. Syringability is measured through a 21G needle using a texture analyzer with a 50 mm/min crosshead speed; the syringe force should not exceed 25 N at 20°C. The terminal dosage form is an injectable suspension for cattle, swine, or sheep, but intravenous administration is contraindicated unless the median microcapsule diameter is reduced below capillary diameter. Published data for such intravenously administered microencapsulated veterinary formulations is limited, so formulation work must rely on product-specific particle-size characterization by laser diffraction according to ISO 13320:2020. Sedimentation volume measured over 24 h should remain above 0.8, and redispersibility is maintained by including a structured vehicle with a yield stress between 0.5 Pa and 2.0 Pa. Avoid combination with amine-based buffering agents such as tris(hydroxymethyl)aminomethane because residual alkaline conditions can accelerate ester hydrolysis of some cellulosic coating grades.

Hard gelatin capsule filling of a microencapsulated veterinary grade API introduces two independent constraints: electrostatic retention of charged shell fragments on the capsule wall and moisture-driven cross-linking of gelatin that can retard dissolution. The dry fill is prepared by geometric dilution: microencapsulated API is pre-blended with lactose monohydrate or dicalcium phosphate dihydrate at a ratio of 20–70 wt% active microcapsules, followed by sodium stearyl fumarate at 0.5–1.0 wt% and colloidal silicon dioxide at 0.2–0.5 wt% as glidant. A tamping-pin capsule filler operating at 30,000–60,000 capsules/h is typically used for production, with pin heights set to produce a final fill mass within ±5% target and an acceptance value not greater than 15 under USP <905>. For products intended for immediate release, USP <711> dissolution is performed in 900 mL of buffered medium at 37±0.5°C using apparatus 2 at 50 rpm. When gelatin capsules are stored above 40°C and 25% RH, pellicle formation from cross-linking can cause Q-value failure even though the same batch passes initially. The processing boundary is therefore not only the powder flow but also the equilibrium moisture content of the shell: conditioning at 20–25°C and 35–45% RH for at least 24 h before filling is required when the facility ambient RH exceeds 60%. Hard hypromellose capsules are an alternative shell material when the antimicrobial preservative system or the microcapsule coating contains reactive aldehyde impurities that independently accelerate gelatin cross-linking. The terminal product is an oral capsule for companion animals or equine administration, filled into PVC/aluminium foil blisters with a desiccant canister to keep shell moisture below 16% w/w.

Water-Soluble Oral Powders and Reconstitution Behaviour

In water-soluble oral powders for drinking-water administration to poultry and swine, the microencapsulated API must remain as a stable particulate during dry storage but disperse quickly upon contact with water at 20–25°C without releasing the total dose before the target animal consumes the medicated water. The powder blend is formulated as a dilutable premix of microencapsulated API at 10–50 wt% in dextrose monohydrate or spray-dried lactose, with sodium lauryl sulfate at 0.1–0.5 wt% as wetting agent and anhydrous citric acid at 0.5–2.0 wt% to control local pH below 6.0. Ribbon blending in a 500 kg capacity trough blender at 15 rpm for 15 min is common, but the fill volume should not exceed 60% of the vessel volume to avoid dead zones at the end plates. Sieving through a 1.0 mm or 850 µm mesh before packaging removes agglomerates formed during blending and protects reconstitution consistency. In use, the powder is diluted into drinking water at final API concentrations of 0.01–0.1% w/v depending on the dose; the reconstituted suspension should have a wetting time below 60 s and should remain homogeneous under intermittent stirring. Homogeneity of the dry powder is assessed by USP <905> or equivalent blend uniformity with an acceptance value ≤15, while moisture content is measured by Karl Fischer titration and controlled below 2% w/w. Storage under 40°C/75% RH for 6 months in aluminium-lined sachets has been used as an accelerated stability condition under VICH GL4, but published data on microencapsulated veterinary API in this exact matrix is limited and should be confirmed with product-specific studies. The terminal product is an oral powder for continuous or pulse medication through nipple drinkers, with the main processing failure being hygroscopic caking when the packaging seam leaks.

Granulated intermediates containing microencapsulated API are typically prepared by top-spray fluid-bed granulation in a Glatt-type or equivalent unit with an inlet air temperature of 50–65°C, a product temperature of 30–40°C, and a spray rate of 10–15 g/min for a 500 g laboratory batch. The granulation liquid is a purified-water solution of polyvinylpyrrolidone K30 at 3–8% w/w, and the dry powder charge consists of microencapsulated API at 25–60 wt%, microcrystalline cellulose PH101 at 20–40 wt%, and lactose monohydrate at the balance. The primary process conflict is water ingression into the microcapsule shell during droplet wetting; this is controlled by maintaining a drying capacity high enough to keep the bed dew point below 12°C and by limiting the granulation liquid-to-solid ratio to 12–18% w/w. After spraying, the granules are dried to a loss-on-drying of 1.0–2.0% w/w and sized through a 1.0 mm or 850 µm screen; granules outside the 250–850 µm fraction are reworked by milling. Particle-size distribution is determined by analytical sieving according to USP <786> and ISO 9276-1:1998. Release as an oral granule for horses or swine involves uniformity of dosage units by USP <905> and dissolution by USP <711> if the granule is filled into unit-dose sachets. The main batch-to-batch variance arises from electrostatic adhesion of fines to the fluid-bed filter bag; this can be reduced by grounding the apparatus and by spraying 0.1–0.3% w/w colloidal silicon dioxide onto the granule surface after drying. The terminal product is a granulated oral dosage form that may be top-dressed on feed or reconstituted with water before administration; if the granules are tabletted later, the dry granulation stage should be replaced with roller compaction at roll pressures below 4 MPa because re-compression of wetted microcapsules risks shell fracture.

At tonnage-scale feed mills, the microencapsulated API is first diluted into a Type A medicated article at 1–10% w/w active in a carrier such as ground corn cob, rice hulls, or calcium carbonate. The dilution is performed in a ribbon blender of 0.5–2 ton capacity at 10–15 rpm for 10–20 min after geometric pre-blending. The feed additive is then incorporated into Type B and Type C medicated feed at final concentrations specified in the approved labelling, commonly 0.01–0.1% w/w depending on the API and target species. Mix uniformity testing during process validation should produce an assay relative standard deviation of ≤10% across 10 sampling points, in line with FDA medicated feed cGMP expectations under 21 CFR 225.1. The finished feed is assayed before release because microencapsulated API can stratify during screw conveyor transfer into bulk storage. Steam conditioning at 70–85°C for 30–60 s before pelleting may partially plasticize ethylcellulose-based wall materials and cause premature release in the feed, while a lipid-coated microcapsule variant with a melting point above 80°C is generally preferred for pelleted rations. VICH residual solvent limits under VICH GL18 are applied to the microcapsule coating because solvents such as methylene chloride and methanol may remain from coating processes; each solvent must be controlled to the permitted concentration in the final premix. The terminal product is a medicated premix for incorporation into broiler, swine, or cattle feed, and the post-pelleting assay shift should be monitored by comparing pre-pellet mash assay against post-pellet assay at three levels: 50%, 100%, and 150% of label claim.

Suspension-In-Solution Drench Stability Depends on Zeta Potential and Flocculation Control

The suspension-in-solution drench stability of microencapsulated API is controlled less by the polymer shell and more by zeta potential, continuous-phase density, and flocculation of free fines released during wetting. In a typical oral drench suspension, the microencapsulated API is incorporated at 5–15% w/v, with xanthan gum at 0.15–0.35% w/v as a suspending agent, sorbitol solution at 5–10% w/v to match the density of the continuous phase, sodium citrate/citric acid buffer at 10–25 mM to hold pH between 5.0 and 6.0, and a preservative system of methylparaben 0.18% w/v and propylparaben 0.02% w/v in accordance with USP <51>. The manufacturing sequence starts with hydration of xanthan gum in Water for Injection at 25°C for 2 h under low-shear mixing, followed by addition of buffer and sorbitol, and final dispersion of microencapsulated API in a high-shear mixer at 1,500 rpm for 10 min. The product is packaged in amber PET bottles with headspace minimized to 5% of the total container volume to reduce oxidative degradation, and the delivered dose uniformity is verified under USP <905>. Zeta potential values more negative than −30 mV at the final pH are typically needed for electrostatic repulsion of microcapsule fines; if zeta potential falls between −10 mV and −30 mV, flocculation occurs and leads to rapid sedimentation and dose non-uniformity. The terminal product is an oral drench suspension for sheep, goats, or cattle, but the formulation is incompatible with high-ionic-strength electrolyte salts above 100 mM, which compress the electrical double layer and promote particle agglomeration. The critical release test for the liquid dosage form is not dissolution in the conventional sense but redispersibility after 24 h storage: the sediment should redisperse with ≤10 manual inversions and the delivered dose uniformity should remain within ±10% of label claim according to USP <905> for the labelled volume.